By Josh Beckerman
Shares of Exicure surged in post-market trading after the company said it was granted a Nasdaq listing extension.
The stock rose 167% to $6.11 from its regular session close of $2.29. That left the shares down 21% this year.
The company said after the close it was granted an extension subject to showing compliance with all applicable listing criteria by Nov. 14. Shares rose 41% Monday after the company reported debt-for-equity exchange agreements with two promissory notes holders.
Exicure last week said it regained compliance with the $1 minimum bid price requirement after previously disclosing several Nasdaq deficiency notices.
In September 2022, the biotechnology company said it would suspend pre-clinical activities, halt all research and development, and would explore strategic alternatives to maximize stockholder value.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
September 18, 2024 18:30 ET (22:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。